A feasibility study of dignity therapy in patients with stage IV colorectal cancer actively receiving second-line chemotherapy

2014 ◽  
Vol 12 (12) ◽  
pp. 446-453 ◽  
Author(s):  
Maxwell Vergo ◽  
Halla Nimeiri ◽  
Mary Mulcahy ◽  
Al Benson ◽  
Linda Emanuel
Keyword(s):  
Colorectal Cancer ◽  
Feasibility Study ◽  
Stage Iv ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Stage Iv Colorectal Cancer ◽  
Dignity Therapy ◽  
Line Chemotherapy

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

2010 ◽  
Vol 29 (5) ◽  
pp. 1038-1044 ◽  
Author(s):  
José María Viéitez ◽  
Manuel Valladares ◽  
Ignacio Peláez ◽  
Luis de Sande González ◽  
Jesús García-Foncillas ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Randomized Phase Ii ◽  
Line Chemotherapy

Determination of a second-line chemotherapy agent for patients with colorectal cancer (CRC) after fluorouracil failure

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3638-3638
Author(s):  
K. Yamashita ◽  
Y. Hirabayashi ◽  
M. Ikeda ◽  
M. Yamamura ◽  
T. Kubozoe ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Chemotherapy Agent ◽  
Line Chemotherapy

scholarly journals The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation

2019 ◽  
Vol 11 ◽  
pp. 175883591882029 ◽  
Author(s):  
Seiichiro Mitani ◽  
Hiroya Taniguchi ◽  
Keiji Sugiyama ◽  
Toshiki Masuishi ◽  
Kazunori Honda ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Prognostic Score ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Colorectal Cancer Patients ◽  
Line Chemotherapy

Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival. Recently, clinical trials have been conducted to improve outcomes of second or later lines of chemotherapy. However, there is a paucity of reference data pertaining to outcomes of second-line chemotherapy and prognostic factors that are relevant only to BRAF mutant patients. Patients and methods: We retrospectively reviewed metastatic colorectal cancer patients with BRAF V600E mutation who underwent second-line chemotherapy between January 2007 and March 2017. We evaluated treatment outcomes and performed prognostic analyses. Results: A total of 52 patients were included. The median progression-free survival and overall survival (OS) were 2.5 [95% confidence interval (CI) = 1.91–4.11] and 6.5 (95% CI = 4.30–9.63) months, respectively. Overall response and disease control rates were 7% and 48%, respectively. All the regimens which elicited a partial response included BRAF inhibitors in combination with anti-epidermal growth factor receptor (EGFR) antibodies. Therefore, the overall response was 0% after exclusion of patients treated with study drugs. Multivariate analysis for OS revealed that the Glasgow Prognostic Score (GPS), elevated lactate dehydrogenase, and poor performance status were independent prognostic factors. In particular, survival curves according to the GPS stratified the patients into distinct risk groups. The median OSs in patients with GPS of 0, 1, and 2 were 9.9, 5.0, and 1.9 months, respectively. Conclusions: Outcomes of second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation were extremely poor. GPS may be useful in future clinical trials.

Sign in / Sign up

Export Citation Format

Share Document